SciELO - Scientific Electronic Library Online

 
vol.28 issue1Metabolic syndrome: A revision of international criteriaSecundary erithrocitosis from congenital heart disease as a cause of pseudohiperkalemia author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Colombiana de Cardiología

Print version ISSN 0120-5633

Abstract

BARRIOS, Dormar D. et al. Rapid desensitization in patients with hypersensitivity to acetylsalicylic acid with indication for dual antiplatelet therapy due to coronary artery disease. A guide for the clinician in the intensive care unit. Rev. Colomb. Cardiol. [online]. 2021, vol.28, n.1, pp.67-73.  Epub Mar 19, 2021. ISSN 0120-5633.  https://doi.org/10.24875/rccar.m21000011.

Acetylsalicylic acid (Aspirin) is an irreversible inhibitor of acetyl cyclooxygenase (COX) and its activity is not restored until new platelets are formed. Its beneficial therapeutic cardiovascular effects have made it the cornerstone of the treatment of patients with coronary artery disease. There is a population of patients with absolute indication for its use, however, the presence or history of hypersensitivity to this molecule leads to a high risk of complications unrelated to their cardiovascular disease. It is vital to know and implement in some of these patients, desensitization protocols for acetyl salicylic acid and in this way to continue the use of this therapeutic strategy necessary and appropriate in this population.

Keywords : Acetylsalicylic acid; Coronary artery disease; Acute myocardial infarction.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )